Laverock Therapeutics

Laverock Therapeutics is a pre-clinical biotechnology company based in London, UK, founded in 2021. The company specializes in its proprietary Gene Editing induced Gene Silencing (GEiGS®) platform, which is designed for developing next-generation, programmable allogeneic cell therapies. Laverock is a spin-out from Tropic Biosciences and holds an exclusive license to apply the GEiGS® technology, originally developed for improving tropical crops, to human therapeutics.

The GEiGS® platform enables precise and durable gene silencing and control, utilizing a computational approach for engineering induced pluripotent stem cells (iPSCs). Key features include cell identity-based control, tunable expression, and adaptive engineering, which enhance the efficacy and safety of cell therapies. Laverock is focused on advancing therapies for Type 1 Diabetes and solid tumor immunotherapy, with plans for pre-clinical candidate selection. The company is also exploring partnerships to expand the potential applications of its technology.